Suppr超能文献

用于治疗周围神经病变的草药制剂 的安全性和有效性。

Safety and Effectiveness of , a Herbal Preparation for Treatment of Peripheral Neuropathy.

机构信息

Pharmacology and Toxicology Department, Centre for Plant Medicine Research, P. O. Box 73, Mampong, Akuapem, Ghana.

Clinical Research Department, Centre for Plant Medicine Research, P. O. Box 73, Mampong, Akuapem, Ghana.

出版信息

Biomed Res Int. 2019 Jul 24;2019:2607872. doi: 10.1155/2019/2607872. eCollection 2019.

Abstract

Mist Antiaris is a herbal decoction for treatment of nervous disorders. Safety and efficacy were evaluated in Sprague-Dawley rats and human patients, respectively. Acute toxicity was assessed by administration of a single 5000 mg/kg oral dose of decoction to a group of six rats. For subchronic toxicity, four groups of six rats each received water (control) or 10, 100, or 200 mg/kg oral doses of decoction daily for eight weeks. Body weight, serum, urine, and hematological profile of the animals in each group were monitored over the period. Effects of treatment on pentobarbital-induced sleeping time and histology of liver, lung, heart, and kidney tissue were assessed at the end of the study. There was no evidence of acute toxicity within 48 hours of the oral dose. Over the 8-week period, body weight increases in Mist Antiaris treatment groups were reduced relative to the control group. There were no significant differences in urine profile, serum biochemistry, hematological parameters, and pentobarbital-induced sleeping time. Tissue histology revealed no differences relative to controls. Assessment of efficacy was by retrospective review of data on patients who presented with peripheral neuropathy. Treatment resulted in 53.7 % of patients reporting complete resolution and 15.7 % showing reduction in neuropathic symptoms. The data demonstrate that there is no toxicity due to subchronic administration of Mist Antiaris in Sprague-Dawley rats. The reduction or resolution of neuropathic symptoms indicated by patents' file data provides evidence to suggest that has antineuropathic effects.

摘要

密蒙花是一种治疗神经紊乱的草药汤剂。安全性和疗效分别在 Sprague-Dawley 大鼠和人类患者中进行了评估。急性毒性通过给予一组 6 只大鼠单次 5000mg/kg 的口服剂量来评估。对于亚慢性毒性,四组 6 只大鼠分别接受水(对照)或 10、100 或 200mg/kg 的口服剂量,每天一次,持续 8 周。在此期间监测每组动物的体重、血清、尿液和血液学特征。在研究结束时评估治疗对戊巴比妥诱导的睡眠时间和肝、肺、心和肾组织的组织学的影响。在口服剂量后 48 小时内没有证据表明存在急性毒性。在 8 周期间,密蒙花治疗组的体重增加与对照组相比减少。尿液特征、血清生化、血液学参数和戊巴比妥诱导的睡眠时间无显著差异。组织学检查与对照组无差异。疗效评估是通过回顾性分析患有周围神经病变的患者的数据。治疗导致 53.7%的患者报告完全缓解,15.7%的患者报告神经病变症状减轻。这些数据表明,密蒙花在 Sprague-Dawley 大鼠中进行亚慢性给药没有毒性。患者病历数据表明神经病变症状减轻或缓解,这表明密蒙花具有抗神经病变作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc0c/6681673/63724e763025/BMRI2019-2607872.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验